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INTRODUCTION
Postpartum haemorrhage (PPH) is a major cause
of maternal mortality worldwide with an estimated
mortality rate of 140,000 per years. The incidence
of postpartum haemorrhage in developed
countries is 5% of deliveries, while in developing
countries is 28% of labour. The causes maternal
mortality of postpartum haemorrhage are due to
80% uterine atony and 10% retained placenta.
Most of these deaths occur within 4 hours after
delivery, is a consequence of the third stage of
labor.1-3
Indonesian Demographic Health Survey in 2012
showed the maternal mortality rate increased from
Abstract
Objective: To compare the dose of oxytocin injected intraumbilicall
towards the duration of the third stage, blood loss volume, hemo-
globin and hematocrit.
Methods: This study is a prospective randomised study with a
control. The control group was given an intramuscular injection of
10 IU oxytocin. The intervention of the three groups intraumbilical
oxytocin treatment dose of 10 IU, 20 IU and 30 IU diluted in 50 ml of
normal saline solution and administered intraumbilically. The
sample selection by purposive sampling and the distribution group
based on systematic random sampling (10 samples each). Data were
taken from the period April 2016-January 2017 with the inclusion
and exclusion criteria. Data were analysed using Chi-square, T-test,
ANOVA and Post hoc tests.
Results: Characteristics study for variables of age, occupation,
parity, education, episiotomy and neonates weight showed homo-
geneous characteristics. The mean duration of the third stage for
all groups was between 366.7  159.0 seconds and 440.1  244.99
seconds. While the average number of postpartum haemorrhage for
all group 61.894  226.3ml and 309.5  110.26 ml. There were no
differences in the dose of oxytocin on the duration of the third
stage (p> 0.05) and the amount of bleeding (p> 0.005). There was a
difference of haemoglobin between intervention group of oxytocin
dose of 10 IU and 30 IU intraumbilical (p = 0.031). There was no
difference between the mean hematocrit levels between the groups
(p> 0.005).
Conclusion: There were no differences in the dose of oxytocin
intraumbilical towards the duration of the third stage, the amount
of bleeding and hematocrit levels. The decrease of haemoglobin
greater in 30 IU intraumbilical significantly.
[Indones J Obstet Gynecol 2018; 6-3: 155-161]
Keywords: duration of the third stage, haemoglobin and hematocrit,
oxytocin intraumbilical, the amount of bleeding
Abstrak
Tujuan: Membandingkan dosis injeksi oksitosin intraumbilikal ter-
hadap lama kala III, jumlah perdarahan pascasalin, hemoglobin danhematokrit.
Metode: Penelitian ini merupakan uji klinis acak dengan pembanding.Kelompok kontrol diberikan injeksi oksitosin 10 IU intramuskular.
Intervensi pada 3 kelompok yaitu kelompok perlakuan oksitosin
intraumbilikal dosis 10 IU, 20 IU dan 30 IU yang dilarutkan dalamsaline 0,9% sebanyak 50 ml  yang diinjeksikan pada vena umbilikal.
Pemilihan sampel secara purposive sampling dan pembagiankelompok berdasarkan sistematik random sampling (10 sampel tiap
kelompok). Data diambil periode April 2016 - Januari 2017 dengan
kriteria inklusi dan eksklusi. Data dianalisis dengan uji Chi square,uji T, Anova dan Post hoc test.
Hasil: Karakteristik umum variabel usia, pekerjaan, paritas,pendidikan, episiotomi dan berat badan neonatus menunjukkan
karakteristik homogen. Rerata lama kala III untuk semua kelompok
adalah antara 366,7  159,0 detik dan 440,1  244,99 detik.
Sedangkan rerata jumlah perdarahan pascasalin untuk semua
kelompok 226,3  61,894 ml dan 309,5  110,26 ml. Tidak adaperbedaan dosis oksitosin terhadap lama kala III (p>0,05) dan
jumlah perdarahan (p>0,005). Ada perbedaan rerata hemoglobin
setelah intervensi oksitosin dosis 10 IU dan 30 IU intraumbilikal(p=0,031). Tidak terdapat perbedaan rerata kadar hematokrit
antara semua kelompok (p>0,005).
Kesimpulan: Tidak ada perbedaan dosis oksitosin intraumbilikal
terhadap lama kala III, jumlah perdarahan dan kadar hematokrit.Ada perbedaan rerata hemoglobin setelah intervensi oksitosin dosis 10
IU dan 30 IU intraumbilikal.
[Maj Obstet Ginekol Indones 2018; 6-3: 155-161]
Kata kunci: hemoglobin dan hematokrit, jumlah perdarahan, lama
kala III, oksitosin intraumbilikal
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228 per 100,000 live births in 2007 to 359 per
100,000 live births in 2012.2 The leading causes of
maternal mortality in Indonesia is postpartum
haemorrhage (28%), eclampsia (24% ) and infec-
tions (11%). Postpartum haemorrhage is bleeding,
or blood loss of more than 500 ml which occurred
after the child is born either before, during, or after
birth placenta.2-4
To prevent postpartum haemorrhages carried
out active management of the third stage. Active
management of the third stage consists of the
injection of oxytocin 10 IU intramuscularly (IM),
massage of uterine fundus and cord traction to
accelerate the delivery of placenta by inducing
uterine contractions.4,5
Oxytocin can be given intramuscularly or intra-
umbilically. The route of intraumbilical oxytocin
will be distributed directly to the oxytocin
receptors in the myometrium thereby the
myometrium will contract better.4,6,7 Result
analysis showed that the active management
of the third stage could reduce postpartum
haemorrhage up to 58%.6,7 Cochrane reviewed the
active management of the third stage reduces the
incidence of postpartum bleeding, shorten the
third stage and the need for trasfusion.4-6
METHODS
This study was a randomised study with a control.
Intervention in the three groups of intraumbilical
oxytocin treatment with the dose of 10 IU, 20 IU
and 30 IU diluted in normal saline 50 ml injected
into the umbilical vein. The control group was
given an intramuscular injection of 10 IU oxytocin.
This research was conducted in the Department of
Obstetrics and Gynecology Hospital Dr. Moh.
Hoesin, Palembang. The research was conducted in
April 2016 to January 2017. The study population
was all pregnant women who gave birth in
Department of Obstetrics and Gynecology Hospital.
Dr. Mohammad Hoesin / Faculty of Medicine,
Universitas Sriwijaya Palembang. The samples
were all pregnant women who gave birth,
qualified inclusion and exclusion criteria.
Sampling was done by purposive sampling and
divided into control group and intervention group
by systematic random sampling. Sample size
calculations with Pocock formula. The number of
samples obtained each study group were ten
respondents. The inclusion criteria were pregnant
women without complication (physiologically),
premature rupture of membranes (PROM) <12
hours. Exclusion criteria of obesity with a body
mass index (BMI) of 35 kg/m2, abnormal uterine
(eg, anatomical abnormalities, fibroids), a blood
disorder in the mother (Von Willebrand disease,
id iopathic  thrombocytopenia  purpura ,
disseminating intravascular coagulation (DIC)),
placental abruption or placenta previa, multiple
pregnancy, polyhydramnios, estimated fetal weight
>3500g, hypertension or preeclampsia, history
of PPH or retained placenta, a history cesarean
section or laparotomy and fetal death.
Material
The materials were disposable syringes 50 ml
Terumo, disposable syringe 3 ml ONEMED,
oxytocin 10 IU (brand Syntocinon® produced by
Novartis), saline solution 0.9% (manufactured by
PT Widatra Bhakti), stopwatch Kadio KD-2005,
glassware Pyrex, digital scales (brand Camry),
sterile gauze and cloth mat or underpad COSMO
Med.
Procedures
Subjects were randomised systematically by the
arrival of the patient. The subject of the first
sequence to 10 specified in the control group of 10
samples, and the subject of the order of 11 to 20
in the Intervention group 10 IU intraumbilical and
so on until 40 samples. All samples were checked
haemoglobin and hematocrit on admission and 2
hours after delivery.
The intervention group after delivered and
clamped umbilical cord was first injected 10 IU
oxytocin were diluted in 50 ml of normal saline
solution to the umbilical vein with the distance
of about 10 cm from the vulva. The second
intervention group were injected 20 IU oxytocin
were dissolved in 50 ml of normal saline solution.
The third intervention group 30 IU oxytocin
dissolved in 50 ml of normal saline solution. Then
do massage cord proximally to the spread of
oxytocin to the placental implantation site. The
control group was injected 10 IU oxytocin intra-
muscular using a 3 ml disposable syringe lateral
upper thigh.
The duration of the third stage is counted
starting after birth neonates, injection of oxytocin
IM or intraumbilical until the placenta is born with
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a stopwatch. The amount of bleeding is calculated
by measuring the blood by using a measuring cup,
then under a cloth or gauze pad and used weighed.
The difference in weight on a sterile pad (under-
pad) and gauze before and after use was converted
into ml (1 g = 1 ml), then weighed with scales
Camry models NS.
Analysis and Interpretation
Data were analysed using Chi-square, T-test,
ANOVA and Post hoc.
RESULT
Experimental research design with pre and post-
test with control to compare the dose injection of
oxytocin intraumbilical was conducted in April
2016 until January 2017 at the General Hospital
Dr. Mohammad Hoesin Palembang. Total samples
of 40 pregnant women who delivered and fulfilled
the inclusion criteria. The amount of bleeding,
duration of the third stage, haemoglobin and
hematocrit each control group and the intervention
will be assessed and compared.
Characteristics of Subjects
The range of respondents age was 14-45 years, and
the largest age group was 20-35 years old as many
as 32 samples (80%). The majority of respondents
do not work or as housewives (92.5%). The
majority of parity was primigravida (47.5%) with
a high school education level was 80%. Majority
of 60% respondents done episiotomy with the
average birth weight of newborns in this study
were 2949  282.95 gram (Table 1).




















<20 1 (25) 1 (25) 1 (25) 1 (25) 4 (100) 0.254
20-35 8 (25) 9 (28.1) 7 (21.9) 8 (25) 32 (100)
>35 1 (25) 0 2 (50) 1 (25) 4 (100)
Address**
Urban area 10 (31.3) 5 (15.6) 8 (25) 9 (28.1) 32 (100) 0.033
Rural area 0 5 (62.5) 2 (25) 1 (12.5) 8 (100)
Occupation*
Housewives 9 (24.3) 10 (27) 8 (21.6) 10 (27) 37 (100) 0.158
Private sector 1 (100) 0 0 0 1 (100)
Teacher 0 0 2 (100) 0 2 (100)
Parity*
0 5 (26.3) 7 (36.8) 3 (13.8) 4 (21.1) 19 (100) 0.515
1 4 (36.4) 1 (9.1) 2 (18.2) 4 (36.4) 11 (100)
2 1 (14.3) 2 (28.6) 3 (42.9) 1 (14.3) 7 (100)
 3 0 0 2 (66.6) 1 (33.4) 3 (100)
Education*
Elementary 0 0 2 (100) 0 2 (100) 0.061
Junior High 2 (100) 0 0 0 2 (100)
Senior High 5 (15.6) 10 (31.2) 7 (21.9) 10 (31.2) 32 (100)
D3/S1 3 (75) 0 1 (25) 0 4 (100)
Episiotomy**
Yes 6 (25) 8 (33.3) 4 (16.7) 6 (25) 24 (100) 0.343
No 4 (25) 2 (12.5) 6 (37.5) 4 (25) 16 (100)
Birth weight
neonates***
3.085  316.27 2.860  307 2.890  261.19 2.960  282 0.297
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Duration of the third stage
The mean time of the third stage for all groups was
between (366.7  159.0 seconds) and (440.1 
244.99 seconds). Mann-Whitney test showed the
distribution of data not normal, followed by a test
of Kruskal Wallis. From the results of Kruskal
Wallis showed there was no difference between
all the intervention group (p = 0.492). It can be
concluded that there was no difference in the
duration of the third stage among the control
group (oxytocin dose of 10 IU IM) with oxytocin
intraumbilical all doses groups (Table 2).
The Blood Loss during The Third Stage
Post Hoc test results obtained probability between
the control group (oxytocin dose of 10 IU IM) at a
dose of 10 IU oxytocin group intraumbilical, a dose
of 20 IU oxytocin intraumbilical, and a dose of 30
IU oxytocin intraumbilical (p>0.05). It can be
concluded that there was no difference in the
number of blood lossamong the control group
(oxytocin dose of 10 IU IM) and intervention
intraumbilicalgroups in all doses of oxytocin
significantly.
Table 2. Comparison of Intraumbilical Oxytocin Dose in the Duration of the Third Stage between the Two Groups
Groups Average  SD Groups Average  SD p­value
Oxytocin dose 10 IU IM 401.4  209.48 Oxytocin dose 10 IUIntraumbilical 366.7  159.09 0.791
Oxytocin dose 20 IU
Intraumbilical 440.1  244.99 0.384
Oxytocin dose 30 IU
Intraumbilical 384.7  314.59 0.185
Oxytocin dose 10 IU
Intraumbilical 366.7  159.09 Oxytocin dose 20 IUIntraumbilical 440.1  244.99 0.427
Oxytocin dose 30 IU
Intraumbilical 384.7  314.59 0.570
Oxytocin dose 20 IU
Intraumbilical 440.1  244.99 Oxytocin dose 30 IUIntraumbilical 384.7  314.59 0.096
Mann Whitney, Kruskal Wallis













p value 309.5  110.261 vs 2 = 0.051
1 vs 3 = 0.952
1 vs 4 = 0.407
226.3  61.894
2 vs 3 = 0.058
2 vs 4 = 0.244
307.0  86.929
3 vs 4 = 0.442
275.0  101.57
Difference in haemoglobin level (g/dl)
p value 0.27  0.791 vs 2 = 0.840
1 vs 3 = 0.230
1 vs 4 = 0.256
0.35  0.43
2 vs 3 = 0.315
2 vs 4 = 0.183
0.33  0.72
3 vs 4 = 0.023
0.65  0.75
Difference in hematocrit level (%)
p value 0.60  2.411 vs 2 = 0.628
1 vs 3 = 0.505
1 vs 4 = 0.278
1.50  1.58
2 vs 3 = 0.855
2 vs 4 = 0.121
0.80  1.99
3 vs 4 = 0.085
1.90  2.51
Post Hoc test (LSD test), p=0.005
Mean  SD
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Comparison  of  Dose  Oxytocin  to  Haemo­
globin
Post Hoc test probability between the control
group (oxytocin dose of 10 IU IM) at a dose of 10
IU oxytocin group intraumbilical, a dose of 20 IU
oxytocin intraumbilical, and a dose of 30 IU
oxytocin intraumbilical >0.05. There was no
difference between the average amount of
bleeding control (doses of 10 IU oxytocin IM) with
all doses of oxytocin intraumbilical significantly.
In addition, the results obtained probability value
was 0.023 between the 20 and 30 IU oxytocin
intraumbilical (p<0.05). There was difference
haemoglobin level of 30 IU oxytocin group
intraumbilical lower than the oxytocin group
20 IU intraumbilical.
Comparison  of  Dose  Oxytocin  to  Hema­
tocrit Levels
Post Hoc test results obtained probability
between the positive control group (oxytocin
dose of 10 IU IM) with all doses of oxytocin
group intraumbilical (p>0.05). There was no
difference of mean hematocrit levels among the
control group with the intervention group
intraumbilical all doses of oxytocin significantly.
DISCUSSION
General characteristics of Chakra research revealed
no significant differences in age, education level
and occupation of respondents.9,10,12 In the study
Movahed was no significant difference between the
parity of the respondents (p = 0.632) with the char-
acteristics of the respondents there are many
primigravid (46%).9,10,15
Episiotomy was performed in 60% of
respondents with average birth weight of
newborns 2949  282.95 grams. Research of
Movahed were mean weight neonates 3303.8 
366.3. Statistically, there was no significant
difference between the variables an episiotomy
or not (p = 0.244) with weight neonates (p =
0.782).11,12
 Based on the analysis there were no
significant differences in age, occupation, parity,
education, episiotomy and weight neonates.
The variable addressed indicates significant value.
Characteristics of research subjects, in general,
have a homogenous result.
The longest duration of the third stage found in
groups of 20 IU oxytocin intraumbilical dose and
shortest found in the oxytocin group an intraum-
bilical dose of 10 IU. From the statistical analysis,
Mann-Whitney and Kruskal Wallis test showed
there was no difference duration of the third stage
between groups (p> 0.05). The results of this study
are supported by Movahed research conducted in
2012 showed a statistically significant in the
oxytocin intraumbilical group could shorten the
time of the third stage than the control group
(4.2  4:11 vs 4:52  5:53 min; p = 0.031). Neither
Puri study conducted in 2012 reported that oxy-
tocin intraumbilical significant reduction in the
duration of the third stage of labour at five study
groups.5,6,10
Highest blood loss was found in the group of an
intramuscular dose of 10 IU oxytocin, and the least
amount of bleeding was found in the group in-
traumbilical dose of 10 IU oxytocin. Statistical
analysis of Post Hoc showed there was no
difference in the amount of bleeding between the
groups (p> 0.05). Chakra obtained the cut-off point
of bleeding in the third stage of 136 ml, effective
when the third stage of bleeding is less than or
equal to 136 ml. The effectiveness of bleeding in
the third stage on the intraumbilical group by 55%
higher compared to the intramuscular group is at
8.3%, a statistically significant correlation based on
the amount of bleeding in the third stage (p =
0.001). Cochrane meta-analysis on 15 studies
suggest a significant borderline; there were no
differences in the duration of the third stage and
the amount of bleeding between the groups with
expectative management intraumbilical oxytocin,
saline only, intramuscular oxytocin and prosta-
glandins. Controversial opinion on oxytocin intra-
umbilical various doses may provide clinical
benefit in reducing the length of the third stage
and the number of haemorrhage research of
Weeks and G. Carroli.8,9,13
Statistical analysis showed there was no
difference between the haemoglobin levels after
intervention dose of 10 IU oxytocin and oxytocin
IM dose of 20 IU intraumbilical. This means that
the dose of 10 IU oxytocin and oxytocin IM dose of
20 IU intraumbilical effective to prevent a decrease
in haemoglobin (p<0.05). While the intervention of
oxytocin dose of 10 IU and 30 IU intraumbilical not
effectively prevent a decrease in haemoglobin
levels was statistically significant (p>0.05). These
results indicate a dose of oxytocin intraumbilical
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small and large are not effective to prevent a
decrease in haemoglobin. Increasing doses of
oxytocin intraumbilical more than 20 IU will lead
to lower haemoglobin levels significant.
In addition to haemoglobin, changes in
hematocrit levels were also assessed in this
study. Statistical analysis showed that there was
difference between the mean hematocrit levels
after intervention dose of 10 IU oxytocin and
oxytocin IM dose of 20 IU intraumbilical. A dose of
10 IU oxytocin and oxytocin IM dose of 20 IU
intraumbilical effective to prevent a decrease in
hematocrit (p>0.05). While the intervention group
oxytocin dose of 10 IU and 30 IU intraumbilical not
effectively prevent a decrease in hematocrit seen
from a decrease in hematocrit levels were
statistically significant (p<0.05). These results
indicated a dose of oxytocin intraumbilical small
and large were not effective to prevent a decrease
in hematocrit. Increasing doses of oxytocin
intraumbilical more than 20 IU would decrease
hematocrit levels.7,8,10
The absence of a significant decrease in haemo-
globin and hematocrit levels in the intervention
group a dose of 10 IU oxytocin and oxytocin IM
dose of 20 IU intraumbilical indicate that
this intervention can prevent postpartum
bleeding.7,8,14,15
Post hoc tests showed the effectiveness of all
doses of oxytocin intraumbilical no different from
the effectiveness of the control of oxytocin.
However, the effectiveness of a dose of 30 IU
oxytocin intraumbilical significantly different with
a dose of 20 IU oxytocin intraumbilical. Haemo-
globin and hematocrit levels after intervention
intraumbilical dose of 30 IU oxytocin lower than
the levels of haemoglobin and hematocrit after
intervention intraumbilical dose of 20 IU oxytocin
so that it can be concluded extra doses of oxytocin
intraumbilical more than 20 IU would not
prevent a decrease in haemoglobin levels and
hematocrit.7,8,15
In theory, exposure to high doses of oxytocin
cause desensitisation and down-regulation on the
oxytocin receptor. Oxytocin receptors are a group
of G protein-coupled receptors (GPCRs). Desensiti-
zation is a process that prevents overstimulation
on cells through two mechanisms. First with the
receptor phosphorylation inhibits the activation of
protein G. Both with binding proteins, called
arrestins, preventing activation of the G protein
that did not happen with the oxytocin receptor
binding.13,15
Research Anisodowleh comparing haemoglobin
in the intervention group with oxytocin 10 IU
dissolved in 20 ml saline compared with oxytocin
20 IU in a solution of Ringer’s lactate 1 l at 100
ml/min intravenously, showed haemoglobin level
was 12.45  0.78 g/dl and 12.49  0.85 g/dl
(p=0782). Haemoglobin levels after 6 hours
of labour are higher in the intervention group
compared to the control group 12.32  0.88 g/dl
vs 11.58  0.86 g/dl, but this difference was not
significant (p=0.23). A decrease haemoglobin
concentration from 1.96 g/dl to 1.2 g/dl in the
intervention group and the control that shows a
positive effect on injection of oxytocin intraumbi-
lical. The differences are not significant due to the
active management of the third stage in the two
groups was performed using a uterotonic and
standards procedure.8,11,12
Research Movahed et al. described the decrease
of haemoglobin levels in the intervention group
who received injections of oxytocin is intraum-
bilical not significantly different with the control
group who received intravenous oxytocin
(p=0.228). So that the injection of oxytocin
intraumbilical concluded no benefit in preventing
postpartum haemorrhage quantified grading
Hb.6,7,10
Puri results explained the significant differences
in levels of haemoglobin and hematocrit on four
intervention groups and one control group. The
concentration of 10 IU oxytocin increased in
groups of 2 to 20 IU in group 3, further reduction
of time in the third stage but the difference was
not statistically significant. Oxytocin concentra-
tions increased to 30 IU (or 0.06 IU/ml) in group
4 significantly reduced the volume of blood , and
there were differences in haemoglobin concentra-
tion and hematocrit before and after childbirth.6
Limitations of this study were the small sample
number and not blinded when the retrieval and
analysis of data. Measurement of the amount of
bleeding was based on the amount of bleeding that
accommodated (underpad, gauze). It was subjec-
tive, not using the colourimetric technique, radio-
labeled red blood cells, gravimetric or dye dilution
method.
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CONCLUSION
Oxytocin intraumbilical 10 IU reduced the duration
of the third stage and blood loss. There were no
differences in the duration of the third stage,
volume blood loss and hematocrit level among
the control group (oxytocin dose of 10 IU IM)
with oxytocin intraumbilical all dose groups
significantly. However, there was a difference
between the mean haemoglobin levels of 20 and
30 IU oxytocin, whereby haemoglobin levels 30 IU
oxytocin group intraumbilical lower than 20 IU
oxytocin group intraumbilical.
SUGGESTION
Oxytocin intraumbilical10 IU could be an alterna-
tive in the active management of the third stage an
action that was not invasive to the mother, easy,
cheap and minimal side effects to prevent post-
partum bleeding. The results are expected to be
used as basic data for more advanced research,
using the number of subjects a larger study and
consider the factors that may be a bias in this
study.
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